IVF

PGT-M is a genetic testing technique designed to identify if there is a single-gene disorder(s) in embryos created through in vitro fertilization (IVF). These disorders, which include conditions such as cystic fibrosis, sickle cell anemia, and Huntington’s disease, are usually caused by mutations in a single gene. By testing embryos for these genetic abnormalities before implantation, couples can select and transfer only those embryos that are free from the targeted disorder (genetic variant), avoiding the risk of passing it on to their children.

Preimplantation Genetic Testing for Human Leukocyte Antigens (PGT-HLA) provides patients with an option not only to avoid an inherited risk when combined with single gene testing (PGT-M), but also to establish a pregnancy with an exact HLA match to benefit an affected family member.

As the title states, non-disclosure involves keeping the at-risk individual’s status for a condition such as Huntington disease, for example, unknown. How can this be done, you may ask?

Having enough frozen specimens to complete your IVF cycles is a positive thing. Not all patients are able to produce or purchase the specimens they need to […]

Screening is now pan-ethnic, and uses DNA platforms. Couples of mixed ethnicities are screened without regard to specific ethnicity. Over 400 disorders can be screened, identifying approximately 2% at-risk couples.

In the world of Preimplantation Genetic Testing (PGT), we begin with an embryo biopsy. The quality of the biopsy is not always the same, in order to […]